The company’s fully biological approach opens the way for a potential curative treatment for CVI, using personalized tissues that eliminates the need for immunosuppressive therapy, it states. The manufacturing process is completed within ten days, making its offering both scalable and clinically feasible, it states further. Trial sites for the Phase II/III study are located in Spain, the Netherlands and Poland.

“This financing enables a critical step forward in our clinical development and is a critical component in our journey to redefine how vascular disease can be treated by restoring natural biological function. With P-TEV, we are addressing a large, underserved patient population with a therapy designed to address the underlying cause of disease, not just manage the symptoms. The initiation of our pivotal trial brings us significantly closer to making this a clinical reality,” says Petter Björquist, CEO, Verigraft.

As an advanced therapy medicinal product (ATMP), Verigraft’s clinical development program is designed to generate robust clinical data in a limited patient population. The company aims to achieve market approval in Europe and the US in 2028.